NASDAQ : ATOS
Atossa Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.17 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 21.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 22.95M |
| Enterprise Value | -3.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.98M |
| Shares Outstanding | 9.98M |
| Shares Change (YoY) | +1.95% |
| Shares Change (QoQ) | +3.32% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 12.58% |
| Float | 9.94M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.69 |
| Quick Ratio | 4.79 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -89.23% |
| Return on Assets (ROA) | -50.69% |
| Return on Invested Capital (ROIC) | -58.05% |
| Return on Capital Employed (ROCE) | -146.30% |
| Weighted Average Cost of Capital (WACC) | 11.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.36M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -82.76% |
| 50-Day Moving Average | 2.42 |
| 200-Day Moving Average | 3.92 |
| Relative Strength Index (RSI) | 45.56 |
| Average Volume (20 Days) | 94,188 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 683,539 |
| Short Previous Month | 788,334 |
| Short % of Shares Out | 6.85% |
| Short % of Float | 6.87% |
| Short Ratio (days to cover) | 7.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.25M |
| Pretax Income | -37.71M |
| Net Income | -37.71M |
| EBITDA | -39.24M |
| EBIT | -39.25M |
| Earnings Per Share (EPS) | -$4.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 26.09M |
| Total Debt | n/a |
| Net Cash | 26.09M |
| Net Cash Per Share | $2.61 |
| Equity (Book Value) | 26.83M |
| Book Value Per Share | 2.69 |
| Working Capital | 25.56M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -35.77M |
| Capital Expenditures | -14,000 |
| Depreciation & Amortization | 16,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -35.78M |
| FCF Per Share | -$3.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.95% |
| Shareholder Yield | -1.95% |
| Earnings Yield | -188.81% |
| FCF Yield | -155.90% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $19.00 |
| Price Target Difference | 726.09% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |